Table 4. Relationship between MSI2 and E-cadherin in CRC.
| Clinicopathological parameters | Total Number of patients | MSI2 protein expression | χ2 | p-value | r | |
|---|---|---|---|---|---|---|
| Low (n. %) | High (n. %) | |||||
| Expression level in primary tumor | ||||||
| E-cadherin in primary tumor | ||||||
| Low | 12 | 3 (25%) | 9 (75%) | 0.000 | 1.000 | -0.040 |
| High | 16 | 5 (32%) | 11 (68%) | |||
| E-cadherin in metastasis | ||||||
| Low | 12 | 5 (42%) | 7 (58%) | 1.750 | 0.186 | 0.333 |
| High | 16 | 2 (12%) | 14 (88%) | |||
| Expression level in metastasis | ||||||
| E-cadherin in primary tumor | ||||||
| Low | 12 | 1 (8%) | 11 (92%) | 0.650 | 0.420 | -0.256 |
| High | 16 | 5 (32%) | 11 (68%) | |||
| E-cadherin in metastasis | ||||||
| Low | 12 | 6 (50%) | 6 (50%) | 4.861 | 0.027 | 0.500 |
| High | 16 | 1 (6%) | 15 (94%) | |||
Categorical data were evaluated using the Pearson χ2 test, adjusted by Yates’s correction for continuity. The correlation coefficients between protein expression and clinical and pathological parameters were estimated using Spearman correlation.